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ABSTRACT 
For quite some time, glaucoma has been regarded as more than just intraocular pressure [IOP] elevation. 
Significant contribution to this conceptual improvement has risen from a better understanding of ocular 
blood flow, vessel wall integrity and certain advanced ideas in neuroophthalmology, for example 
neuroprotection. Transforming growth factor–β (TGF-β) molecule, its inhibitors and antagonists have been 
increasingly researched as possible new anti-glaucoma drugs for its many, pleiotropic, effects. Among those 
effects, enhancing fibrosis is one of the most apparent, but certain members of this cytokine’s superfamily 
act as anti-fibrotics. Recent scientific efforts strongly support pushing back the frontier of conventional 
medical treatment. Current medical approaches already use effects on blood flow and neuronal 
quiescence, with significant systemic side-effects. Endeavours on the ophthalmologic exploitation of 
selected, favourable effects of pleiotropic TGF-βs could promote TGF-β, its inhibitors or specific antibodies 
as new, ideal drugs in glaucoma therapy. 
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INTRODUCTION  
Glaucoma, a progressive optic neuropathy [1,2], is the second 
leading cause of vision loss. The vascular theory of glaucoma 
considers optic neuropathy as a consequence of blood supply 
that is jeopardised by a reduced ocular blood flow [3,4]. Ocular 
blood flow is an extremely complex process, as metabolic 
needs follow changes in visual function [5-10].  
In vitro studies have suggested that transforming growth 
factor-β [TGF-β] signalling pathways regulate angiogenesis 
[11,12]. This originates from ALK-1 [13] and -5. Both act 
through receptor-regulated SMADs, though via different 
methods [14]. Mostly, SMADs are bone morphogenetic protein 
[BMP]-dependent, and are activated in various animal tissues 
[15]. In pulmonary or hepatic fibrosis, systemic sclerosis, 
glomerulosclerosis or in dermal scarring, there is noticeable 
evidence that TGF-β mediates a pathological increase in 
extracellular matrix deposition [16-20]. Although not all 
members of this superfamily act as pro-fibrotics [12,15,16,20], 
TGF-β was found to increase extracellular matrix proteins in the 
optic nerve [21], and affect rabbit sub-conjunctival fibroblasts 
[22].   
Endothelium 
BMPs play an important role in endothelial cell [EC] function 
[23-26]. Interestingly, different ECs are differently susceptible 
to different isoforms of TGF-β. BMP-4 and -6 [members of the 
TGF-β superfamily] promote EC migration and proliferation 
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[27], while BMP-9 is a circulating vascular quiescence factor 
[28]. Vascular endothelium releases different vasoactive factors 
that regulate the microcirculation [29,30]. Previously, BMP-2, -
4, and -7 have been reported to bind ALK1 receptors and EC, 
which are targets for certain ligands of the BMP members of 
the TGF family [23]. Vascular endothelial dysfunction is a 
frequent basis of many diseases [31,32]. Dysfunction in the 
endothelium can influence the vessel’s diameter and 
resistance.  
Reduced levels of nitric oxide [NO] can result in decreased 
vasodilatation and increased vasoconstriction [33-35] 
connected consecutively by a decrease in nitrosylation [36] and 
fragmentation of DNA, all of which lead to apoptosis [37]. Low 
levels of nitric oxide reduce blood flow as in glaucoma. 
Compromised availability of NO as well as an imbalance 
between NO and endothelin-1 [ET-1] have been reported in 
glaucoma patients [38]. Patients with normal-tension glaucoma 
have increased plasma, and those with open angle glaucoma 
have aqueous humor levels of ET-1 [39,40]. Vasoconstriction 
inevitably leads to hypoxia, which makes it reasonable to 
suppose that various cytokines may be up-regulated in 
glaucoma [41,42]. 
Ocular Blood Flow 
Researchers have long reported that patients with open-angle 
glaucoma exert altered blood flow in retinal, choroid, and 
retro-bulbar circulation [5-9,43]. An alteration in the eye blood 
supply can be further correlated to vascular endothelial 
dysfunction [31,32]. The narrowing of blood vessels increases 
resistance to flow distally, which leads to hypoxia. Several 
population-based studies documented retinal vascular 
narrowing. Structural changes might increase flow resistance, 
or might result in functional dysregulation of the vascular 
width. Reduction in the blood flow is not only limited to the eye 
but to the orbit and even the periphery. In some patients, 
blood flow reduction precedes glaucoma [44]. Intraocular 
pressure [IOP] alone is unlikely to cause the disruption of ocular 
blood flow more distinctly in normal-tension patients than 
high-tension ones. Reduced perfusion pressure could result in 
increased IOP or decreased blood pressure [44-46], and the 
increased viscosity of blood can be a result of a blood dyscrasia. 
Neuroprotection of TGF-β 
Due to its pleiotropy, the beneficial effect of TGF-β on vascular 
integrity has been easy to understand. That effect is not 
impossible to link to its many different functions, like local 
neuroprotective humoral agents or mediator in embryogenesis. 
The objective is to connect its vascular quiescence to the 
established endothelial NO production in order to influence 
cerebral perfusion [48]. Furthermore, TGF-β as the vascular-
integrity guard ensures the preservation of the vessel wall, thus 
eliminating factors required for scarring. TGF-β mRNA is 
elevated for at least a week after a stroke and clearly exerts a 
neuroprotective role [48]. Nevertheless, in order to exploit the 
therapeutic properties of TGF-β, any additional roles in the 
brain after stroke should be clearly understood. However, the 
acute abolition of blood supply, as in strokes, should not be 
compared to long-lasting, chronic diseases, like glaucoma. 
Moreover, not all TGF-β members exhibit pro-fibrotic actions.  
Thanks to the neuroprotective effects of TGF-β [47-49], it is 
considered a future important target for therapy following a 
stroke. The precise function of increased TGF-β after stroke is 
unknown and due to its pleiotropic nature, it might well 
modulate NO production by ECs, orchestrate glial scarring, or 
function as a significant immune system regulator. Even NO is 
potentially neurotoxic, due to the reaction with superoxide 
anions, which produce reactive free radical species. 
  
HYPOTHESIS 
The ideal anti-glaucoma drug would prevent cell death of the 
retina with no adverse effects. However, a more realistic ideal 
drug would be one that reduces IOP, and reaches the retina in 
appropriate amounts to reduce retinal cell death, even if 
applied topically [2,45,50]. A variety of agents may act on 
growth factors, including TGF-β. Employing antibodies against 
the TGF-β superfamily members that are involved in 
angiogenesis and vessel quiescence as a treatment option for 
glaucoma is not new. One of the theoretical advantages of the 
human TGF-β2 antibody [which is the predominant form in the 
aqueous] is that it only acts if there is TGF-β2 in the wound, 
unlike an anti-metabolite [51]. Even if all of the above is 
neglected, the vasoconstrictive effect of ET-1, mediated by TGF-
β-stimulated ALK-5 remains an open option. The employment 
of inhibitors of TGF-β in glaucoma therapy is also not new. N-
[3', 4'—dimethoxycinnamoyl]anthranilic acid inhibits TGF-β 
activity and has anti-scarring effects in the body and the eye 
[52]. Interferon-α, an anti-fibrotic cytokine, has been shown to 
reduce the scarring activity of fibroblasts, although a clinical 
trial did not show it to be significantly better than current anti-
metabolites [53]. 
With respect to vascular theory on the aetiology of glaucoma, 
the possible involvement of the TGF-β signalling system in the 
treatment approach of glaucoma is hypothesised, regarding 
endothelial dysfunction, ocular blood flow and neuroprotective 
features of TGF-β. This should be based on the inhibition of the 
pathological accumulation of the extracellular matrix and the 
modulation of fibrotic mechanisms with new anti-fibrotic 
agents. Further confirmation is needed to elucidate whether 
the cross-talk of TGF-β with other pathway systems already 
employed in the therapy of glaucoma exists. Also, it is 
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important to fully understand any possible impact of any TGF-β 
superfamily members on complex pathophysiological 
mechanisms in glaucoma.  
 
DISCUSSION 
The vascular theory suggests that insufficient blood supply 
results in glaucoma. Conditions such as normal-tension 
glaucoma are among the chief strongholds to this theory. The 
reduction of ocular blood flow often precedes glaucomatous 
damage. Other parts of the body in glaucoma patients might 
also exert reduced blood flow, e.g. the extremities. 
Additionally, there is an increased prevalence of ischaemic 
lesions in other organs of the body that result in hearing 
problems, heart attacks, and small strokes in these patients. 
Vascular dysregulation in arteriosclerosis leads to low 
profusion. Glaucoma is only faintly related to arteriosclerosis. 
The relationship between treatment with antihypertensive 
medication in glaucoma-free subjects and structural changes in 
the optic disc was established by epidemiologic cross-sectional 
studies [44,54]. Increased IOP is, to some extent, associated 
with high blood pressure, but glaucoma is linked to low blood 
pressure [44]. Finally, patients with a decrease in blood 
pressure while sleeping may have a higher risk of glaucoma 
progression. Low perfusion pressure is compensated by auto-
regulation, ensuring normal perfusion. There are indications 
that this auto-regulation is altered in some patients with 
glaucoma.    
Vascular conditions, such as Raynaud’s disease, apnoea during 
sleep [55], and migraine headaches, are all associated with 
glaucoma. Raynaud’s disease may be an indicator for normal-
tension glaucoma. Sleep apnoea is not necessarily a vascular 
condition, although decreased breathing means diminutions in 
the intake of oxygen. Migraine headaches may indicate 
decreased blood flow to areas of the brain. Atrial fibrillation, 
possibly causing irregular flow states, is also associated. Loss of 
blood, haemorrhage, or the necessity for a blood transfusion, 
can also cause glaucomatous defects in the optic nerve and 
visual field [56,57].  
It is almost certain that obesity would be risk factor for both 
increased IOP and for arteriosclerosis. High cholesterol is also a 
risk factor for increased IOP, but not for normal-tension 
glaucoma. Normal-tension glaucoma patients tend to have a 
lower body mass index [58], and smoking and diabetes are 
associated with increased IOP but not with glaucoma. Men tend 
to have more, and earlier, arteriosclerotic plaques, but women 
are actually at a higher risk for normal-tension glaucoma 
[59,60].   
Indirect signs of altered blood flow in the eye include changes 
in conjunctival capillaries. Something less evident, however, is 
local vasoconstriction in the retina. An increased frequency of 
optic disc haemorrhages and gliosis-like alterations are 
indicators for altered blood flow. Disc haemorrhages occur in all 
stages of the disease and are more frequent in normal-tension 
glaucoma [61].    
Since the heart cycle significantly reflects the arterial blood 
flow to the eye, the volume of all ocular sheets [especially of 
the choroid] and the IOP are highest during systole [62]. A 
connection of vasculature and glaucoma should be sought in a 
decrease of blood flow [5-9,31,32,43]. Decreased blood influx 
to the optic nerve might be either due to decreased blood 
pressure, narrowing of the vessels or due to increased IOP 
[41,44]. Decreased circulation follows decreased blood flow or 
decreased perfusion, which could result in increased optic 
nerve damage that is comparable to ischaemia of the heart or 
brain [30,41]. 
Medications could be used to lower IOP. Several different 
classes of medications are used in glaucoma management 
[63,64]. None of these is unfettered with both local and 
systemic side-effects. If they occur, the patient must be willing 
either to tolerate these, or to communicate with the treating 
physician to improve the drug regimen. Poor compliance with 
treatment regimes and follow-up visits is a major reason for 
disease progression to blindness in glaucoma patients. Patient 
education and communication must be the target of any 
successful therapy. 
Various cytokines are released as a response to tissue injury 
[65], i.e. a breakdown in the blood—aqueous barrier [66], 
which may not be clinically visible. This feature was established 
for numerous agents active on a cellular level, including 
cytokines and growth factors. Because of their significance, 
tissue scarring, inhibition or antagonism of this action was the 
focus of glaucoma therapy.  
Therefore, in the therapy of glaucoma, fibrinolytic agents have 
had their place [67] as they may lower IOP, however, a risk of 
further extra- and intraocular haemorrhage should not be 
neglected [68]. Fibroblast activation has also been a target of 
anti-glaucoma therapy [69]. 
However, considering all of these molecules, they may have a 
longer-term stimulatory effect on wound healing when 
breaking down. The prevention of clotting may be a more 
promising avenue. 
Gingko biloba extract is one of the supplements that has been 
given to patients most frequently [70,71], and may increase 
peripheral blood flow [72]. A diet high in antioxidants has been 
believed to reduce the risk of glaucoma [73]. However, none of 
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the supplements have been proven in randomised controlled 
trials.   
It is possible that, irrespective of IOP, various strains can 
damage the connective tissue of the optic nerve and axons. 
Reduced ocular blood flow, perhaps adjoined by underlying 
vascular disease, is directly involved in the pathophysiology of 
glaucoma. Dysregulation or an inadequate vasomotor activity in 
some glaucoma patients is often combined with widening 
vessels in neighbouring tissues. This decreases the adjusting 
capacity for the different flow states in decreasing blood flow 
to the nerve, and thereby causes the subsequent progression of 
the glaucoma.   
Certain carbonic anhydrase inhibitors have been shown to 
possibly increase ocular perfusion and produce a short-term 
improvement in the visual field [56,63]. The potential 
neuroprotective effects of various topical and systemic 
medications are also being investigated. In this way, the role of 
TGF-β, its inhibition or deleting its effect by coupling with 
polyclonal antibodies, needs to be viewed and evaluated as a 
possible ideal drug for glaucoma therapy. 
 
CONCLUSIONS 
There is a need to improve the technology for the 
measurement of ocular blood flow, since studies are still at the 
stage of simply lowering IOP [45]. Next, a requirement exists for 
establishing data by comparing glaucoma patients to normal 
individuals and to identify subgroups of those with glaucoma. 
After setting out all of the parameters, it will be possible to 
correlate these findings with optic nerve and visual field 
damage. That might, perhaps target vascular dysregulation to 
treat glaucoma patients. At present, no medication exists to 
increase ocular perfusion.   
Neuroprotection is appreciated for the very absence of the 
need to treat the cause of the disease. Neuroprotective 
medications are, however, still being explored, and could 
provide protection to such neurons that continue to remain at 
risk. Neuroprotection attempts to address the common way of 
an insult, regardless of its cause. 
The neuroprotective role of α2-adrenergic receptor agonists in 
the retina seems to be gaining importance in the treatment of 
glaucoma. However, the exact mechanism [supposedly 
transactivation] by which an α2-adrenergic agonist exhibits 
neuroprotection of neuronal elements in the retina still remains 
to be proven [74]. 
Endothelial integrity, blood flow, and glaucoma are active and 
dynamic fields that will, in the future, given adequate attention, 
interest, and scientific research, produce results that will help 
treat and withhold the progression of glaucoma.    
DISCLOSURE 
The authors report no conflicts of interest in this work. 
 
REFERENCES 
1. Infeld DA, O'Shea JG. Glaucoma: diagnosis and management. 
Postgrad Med J. 1998 Dec;74(878):709-15. PMID: 10320884.  
2. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am 
J Health Syst Pharm. 2005 Apr 1;62(7):691-9. PMID: 15790795. 
3. Flammer J. The vascular concept of glaucoma. Surv Ophthalmol. 1994 
May;38 Suppl:S3-6. PMID: 7940146.  
4. Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, Martin B. 
Vascular aspects in the pathophysiology of glaucomatous optic 
neuropathy. Surv Ophthalmol. 1999 Jun;43 Suppl 1:S43-50. PMID: 
10416746.  
5. Harris A, Chung HS, Ciulla TA, Kagemann L. Progress in measurement 
of ocular blood flow and relevance to our understanding of glaucoma 
and age-related macular degeneration. Prog Retin Eye Res. 1999 
Sep;18(5):669-87. PMID: 10438154.  
6. Resch H, Karl K, Weigert G, Wolzt M, Hommer A, Schmetterer L, 
Garhöfer G. Effect of dual endothelin receptor blockade on ocular 
blood flow in patients with glaucoma and healthy subjects. Invest 
Ophthalmol Vis Sci. 2009 Jan;50(1):358-63. PMID: 18719081.  
7. Flammer J, Orgül S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, 
Renard JP, Stefánsson E. The impact of ocular blood flow in glaucoma. 
Prog Retin Eye Res. 2002 Jul;21(4):359-93. PMID: 12150988. 
8. Emre M, Orgül S, Gugleta K, Flammer J. Ocular blood flow alteration 
in glaucoma is related to systemic vascular dysregulation. Br J 
Ophthalmol. 2004 May;88(5):662-6. PMID: 15090420.  
9. Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Opin 
Ophthalmol. 2005 Apr;16(2):79-83. PMID: 15744136.  
10. Yu DY, Su EN, Cringle SJ, Yu PK. Isolated preparations of ocular 
vasculature and their applications in ophthalmic research. Prog Retin 
Eye Res. 2003 Mar;22(2):135-69. PMID: 12604056. 
11. Orlova VV, Liu Z, Goumans MJ, ten Dijke P. Controlling angiogenesis 
by two unique TGF-β type I receptor signaling pathways. Histol 
Histopathol. 2011 Sep;26(9):1219-30. PMID: 21751154.  
12. Pardali E, Goumans MJ, ten Dijke P. Signaling by members of the 
TGF-beta family in vascular morphogenesis and disease. Trends Cell 
Biol. 2010 Sep;20(9):556-67. PMID: 20656490.  
13. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono 
K, ten Dijke P, Kim S, Li E. Activin receptor-like kinase 1 modulates 
transforming growth factor-beta 1 signaling in the regulation of 
angiogenesis. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2626-31. 
PMID: 10716993. 
14. Wrana JL. Crossing Smads. Sci STKE. 2000 Mar 14;2000(23):re1. 
PMID: 11752591.  
15. Mehra A, Wrana JL. TGF-beta and the Smad signal transduction 
pathway. Biochem Cell Biol. 2002;80(5):605-22. PMID: 12440701. 
 
 
MEHDI Ophthalmology Journal 2012; Vol. 1, No 3     
 
61 REVIEW ON HYPOTHETICAL IMPLEMENTING TGF-Β FAMILY MEMBERS IN GLAUCOMA THERAPY 
16. Verrecchia F, Mauviel A, Farge D. Transforming growth factor-beta 
signaling through the Smad proteins: role in systemic sclerosis. 
Autoimmun Rev. 2006 Oct;5(8):563-9. PMID: 17027893. 
17. Pannu J, Trojanowska M. Recent advances in fibroblast signaling 
and biology in scleroderma. Curr Opin Rheumatol. 2004 Nov;16(6):739-
45. PMID: 15577613.  
18. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic 
sclerosis. J Dermatol Sci. 2008 Feb;49(2):103-13. PMID: 17628443. 
19. Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm 
D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J. 
Progressive transforming growth factor beta1-induced lung fibrosis is 
blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care 
Med. 2005 Apr 15;171(8):889-98. PMID: 15563636.  
20. Wells RG. Fibrogenesis. V. TGF-beta signaling pathways. Am J 
Physiol Gastrointest Liver Physiol. 2000 Nov;279(5):G845-50. PMID: 
11052979. 
21. Zode GS, Sethi A, Brun-Zinkernagel AM, Chang IF, Clark AF, 
Wordinger RJ. Transforming growth factor-ß2 increases extracellular 
matrix proteins in optic nerve head cells via activation of the Smad 
signaling pathway. Mol Vis. 2011;17:1745-58.  
22. Jung SA, Lee HK, Yoon JS, Kim SJ, Kim CY, Song H, Hwang KC, Lee JB, 
Lee JH. Upregulation of TGF-beta-induced tissue transglutaminase 
expression by PI3K-Akt pathway activation in human subconjunctival 
fibroblasts. Invest Ophthalmol Vis Sci. 2007 May;48(5):1952-8. PMID: 
17460246.  
23. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of 
BMP9 and BMP10 as functional activators of the orphan activin 
receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007 Mar 
1;109(5):1953-61. PMID: 17068149. 
24. Huylebroeck D. Bone morphogenetic proteins go endothelial . 
Blood. 2007 mar; 109(5):1794-1795.  
25. Gangopahyay A, Oran M, Bauer EM, Wertz JW, Comhair SA, 
Erzurum SC, Bauer PM. Bone morphogenetic protein receptor II is a 
novel mediator of endothelial nitric-oxide synthase activation. J Biol 
Chem. 2011 Sep 23;286(38):33134-40. PMID: 21808054.  
26. Ricard N, Ciais D, Levet S, Subileau M, Mallet C, Zimmers TA, Lee SJ, 
Bidart M, Feige JJ, Bailly S. BMP9 and BMP10 are critical for postnatal 
retinal vascular remodeling. Blood. 2012 Jun 21;119(25):6162-71. 
PMID: 22566602.  
27. Tian XY, Yung LH, Wong WT, Liu J, Leung FP, Liu L, Chen Y, Kong SK, 
Kwan KM, Ng SM, Lai PB, Yung LM, Yao X, Huang Y. Bone morphogenic 
protein-4 induces endothelial cell apoptosis through oxidative stress-
dependent p38MAPK and JNK pathway. J Mol Cell Cardiol. 2012 
Jan;52(1):237-44. PMID: 22064324.  
28. David L, Mallet C, Keramidas M, Lamandé N, Gasc JM, Dupuis-Girod 
S, Plauchu H, Feige JJ, Bailly S. Bone morphogenetic protein-9 is a 
circulating vascular quiescence factor. Circ Res. 2008 Apr 
25;102(8):914-22. PMID: 18309101. 
29. Orgül S, Prünte C, Flammer J. Endothelium-derived vasoactive 
substances relevant to normal-tension glaucoma. Curr Opin 
Ophthalmol. 1998 Apr;9(2):88-94. PMID: 10180520.  
30. Prünte C, Orgül S, Flammer J. Abnormalities of microcirculation in 
glaucoma: facts and hints. Curr Opin Ophthalmol. 1998 Apr;9(2):50-5. 
PMID: 10180514.  
31. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of 
assessment and application to hypertension. Curr Pharm Des. 
2004;10(29):3591-605. PMID: 15579056.  
32. Drexler H, Hornig B. Endothelial dysfunction in human disease. J 
Mol Cell Cardiol. 1999 Jan;31(1):51-60. PMID: 10072715.  
33. Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide synthase 
2 by aminoguanidine provides neuroprotection of retinal ganglion cells 
in a rat model of chronic glaucoma. Proc Natl Acad Sci U S A. 1999 Aug 
17;96(17):9944-8. PMID: 10449799.  
34. Neufeld AH. Nitric oxide: a potential mediator of retinal ganglion 
cell damage in glaucoma. Surv Ophthalmol. 1999 Jun;43 Suppl 1:S129-
35. PMID: 10416755.  
35. Morgan J, Caprioli J, Koseki Y. Nitric oxide mediates excitotoxic and 
anoxic damage in rat retinal ganglion cells cocultured with astroglia. 
Arch Ophthalmol. 1999 Nov;117(11):1524-9. PMID: 10565522.  
36. Tang CH, Wei W, Liu L. Regulation of DNA repair by S-nitrosylation. 
Biochim Biophys Acta. 2012 Jun;1820(6):730-5. PMID: 21571039.  
37. Taylor EL, Megson IL, Haslett C, Rossi AG. Dissociation of DNA 
fragmentation from other hallmarks of apoptosis in nitric oxide-treated 
neutrophils: differences between individual nitric oxide donor drugs. 
Biochem Biophys Res Commun. 2001 Dec 21;289(5):1229-36. PMID: 
11741325.  
38. Chang CJ, Chiang CH, Chow JC, Lu DW. Aqueous humor nitric oxide 
levels differ in patients with different types of glaucoma. J Ocul 
Pharmacol Ther. 2000 Oct;16(5):399-406. PMID: 11110031. 
39. Tezel G, Kass MA, Kolker AE, Becker B, Wax MB. Plasma and 
aqueous humor endothelin levels in primary open-angle glaucoma. J 
Glaucoma. 1997 Apr;6(2):83-9. PMID: 9098815.  
40. Resch H, Garhofer G, Fuchsjäger-Mayrl G, Hommer A, Schmetterer 
L. Endothelial dysfunction in glaucoma. Acta Ophthalmol. 2009 
Feb;87(1):4-12. PMID: 18507728. 
41. Stefánsson E, Pedersen DB, Jensen PK, la Cour M, Kiilgaard JF, Bang 
K, Eysteinsson T. Optic nerve oxygenation. Prog Retin Eye Res. 2005 
May;24(3):307-32. PMID: 15708831.  
42. Gass A, Flammer J, Linder L, Romerio SC, Gasser P, Haefeli WE. 
Inverse correlation between endothelin-1-induced peripheral 
microvascular vasoconstriction and blood pressure in glaucoma 
patients. Graefes Arch Clin Exp Ophthalmol. 1997 Oct;235(10):634-8. 
PMID: 9349947.  
43. Wilensky JT. The role of diurnal pressure measurements in the 
management of open angle glaucoma. Curr Opin Ophthalmol. 2004 
Apr;15(2):90-2. PMID: 15021217.  
44. Caprioli J, Coleman AL; Blood Flow in Glaucoma Discussion. Blood 
pressure, perfusion pressure, and glaucoma. Am J Ophthalmol. 2010 
May;149(5):704-12. PMID: 20399924.  
45. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; 
Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure 
 
 
MEHDI Ophthalmology Journal 2012; Vol. 1, No 3     
 
62 REVIEW ON HYPOTHETICAL IMPLEMENTING TGF-Β FAMILY MEMBERS IN GLAUCOMA THERAPY 
and glaucoma progression: results from the Early Manifest Glaucoma 
Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79. PMID: 12365904.  
46. Shields MB. Normal-tension glaucoma: is it different from primary 
open-angle glaucoma? Curr Opin Ophthalmol. 2008 Mar;19(2):85-8. 
PMID: 18301279.  
47. Doyle KP, Cekanaviciute E, Mamer LE, Buckwalter MS. TGFβ 
signaling in the brain increases with aging and signals to astrocytes and 
innate immune cells in the weeks after stroke. J Neuroinflammation. 
2010 Oct 11;7:62. PMID: 20937129. 
48. Kaushik S, Pandav SS, Ram J. Neuroprotection in glaucoma. J 
Postgrad Med. 2003 Jan-Mar;49(1):90-5. PMID: 12865582. 
49. García-Campos J, Villena A, Díaz F, Vidal L, Moreno M, Pérez de 
Vargas I. Morphological and functional changes in experimental ocular 
hypertension and role of neuroprotective drugs. Histol Histopathol. 
2007 Dec;22(12):1399-411. PMID: 17701920.  
50. Grieshaber MC, Flammer J. Is the medication used to achieve the 
target intraocular pressure in glaucoma therapy of relevance?--an 
exemplary analysis on the basis of two beta-blockers. Prog Retin Eye 
Res. 2010 Jan;29(1):79-93. PMID: 19733652.  
51. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in 
glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye 
Res. 1994 Dec;59(6):723-7. PMID: 7698265. 
52. Ito S, Sakamoto T, Tahara Y, Goto Y, Akazawa K, Ishibashi T, Inomata 
H. The effect of tranilast on experimental proliferative 
vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1999 
Aug;237(8):691-6. PMID: 10459620.  
53. Zimmerman TJ, Leader B, Kaufman HE. Advances in ocular 
pharmacology. Annu Rev Pharmacol Toxicol. 1980;20:415-28. PMID: 
6155823.  
54. Bhargava M, Ikram MK, Wong TY. How does hypertension affect 
your eyes? J Hum Hypertens. 2012 Feb;26(2):71-83. PMID: 21509040.  
55. Faridi O, Park SC, Liebmann JM, Ritch R. Glaucoma and obstructive 
sleep apnoea syndrome. Clin Experiment Ophthalmol. 2012 May-
Jun;40(4):408-19. PMID: 22339817.  
56. Schor KS, De Moraes CG, Teng CC, Tello C, Liebmann JM, Ritch R. 
Rates of visual field progression in distinct optic disc phenotypes. Clin 
Experiment Ophthalmol. 2012 Sep-Oct;40(7):706-12. PMID: 22429789.   
57. Krudysz J. Effect of transfusions of stored blood and blood-
substitutes on the intraocular tension. Pol Med J. 1966;5(5):1124-31. 
PMID: 5958800. 
58. Gasser P, Stümpfig D, Schötzau A, Ackermann-Liebrich U, Flammer 
J. Body mass index in glaucoma. J Glaucoma. 1999 Feb;8(1):8-11. PMID: 
10084268.  
59. Coleman AL, Kodjebacheva G. Risk factors for glaucoma needing 
more attention. Open Ophthalmol J. 2009 Sep 17;3:38-42. PMID: 
19816585.  
60. Renard JP, Rouland JF, Bron A, Sellem E, Nordmann JP, Baudouin C, 
Denis P, Villain M, Chaine G, Colin J, de Pouvourville G, Pinchinat S, 
Moore N, Estephan M, Delcourt C. Nutritional, lifestyle and 
environmental factors in ocular hypertension and primary open-angle 
glaucoma: an exploratory case-control study. Acta Ophthalmol. 2012 
Mar 6. [Epub ahead of print] PMID: 22394398. 
61. Orgül S, Flammer J. Optic-disc hemorrhages: Cause or result of 
ischemia?. Neuro-ophthalmology. 1994;14(2):97–101.  
62. Singh K, Dion C, Costantino S, Wajszilber M, Lesk MR, Ozaki T. 
Development of a novel instrument to measure the pulsatile movement 
of ocular tissues. Exp Eye Res. 2010 Jul;91(1):63-8. PMID: 20398654.  
63. Lee AJ, Goldberg I. Emerging drugs for ocular hypertension. Expert 
Opin Emerg Drugs. 2011 Mar;16(1):137-61. PMID: 21352074.  
64. Marquis RE, Whitson JT. Management of glaucoma: focus on 
pharmacological therapy. Drugs Aging. 2005;22(1):1-21. PMID: 
15663346.  
65. Hopkins SJ. The pathophysiological role of cytokines. Leg Med 
(Tokyo). 2003 Mar;5 Suppl 1:S45-57. PMID: 12935551. 
66. Haurigot V, Villacampa P, Ribera A, Llombart C, Bosch A, Nacher V, 
Ramos D, Ayuso E, Segovia JC, Bueren JA, Ruberte J, Bosch F. Increased 
intraocular insulin-like growth factor-I triggers blood-retinal barrier 
breakdown. J Biol Chem. 2009 Aug 21;284(34):22961-9. PMID: 
19473988.  
67. Zalta AH, Sweeney CP, Zalta AK, Kaufman AH. Intracameral tissue 
plasminogen activator use in a large series of eyes with valved 
glaucoma drainage implants. Arch Ophthalmol. 2002 Nov;120(11):1487-
93. PMID: 12427061.  
68. Azuara-Blanco A, Wilson RP. Intraocular and extraocular bleeding 
after intracameral injection of tissue plasminogen activator. Br J 
Ophthalmol. 1998 Nov;82(11):1345-6. PMID: 9924355. 
69. Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, Larkin 
G. Activation and suppression of fibroblast function. Eye (Lond). 1994;8 
( Pt 2):188-95. PMID: 7958020. 
70. Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: an 
adjuvant therapy for progressive normal and high tension glaucoma. 
Mol Vis. 2012;18:390-402. PMID: 22355250. 
71. Parikh RS, Parikh SR. Alternative therapy in glaucoma management: 
is there any role? Indian J Ophthalmol. 2011 Jan;59 Suppl:S158-60. 
PMID: 21150028.  
72. Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ. Short-term effects 
of Ginkgo biloba extract on peripapillary retinal blood flow in normal 
tension glaucoma. Korean J Ophthalmol. 2011 Oct;25(5):323-8. PMID: 
21976939.  
73. Lugasi A, Horvahovich P, Dworschák E. Additional information to the 
in vitro antioxidant activity of Ginkgo biloba L. Phytother Res. 1999 
Mar;13(2):160-2. PMID: 10190193.  
74. Arthur S, Cantor LB. Update on the role of alpha-agonists in 
glaucoma management. Exp Eye Res. 2011 Sep;93(3):271-83. PMID: 
21524649. 
